CANF ▲ +10.1% - Can-Fite BioPharma Ltd.
$CANF - Can-Fite Presents Final Positive Data from Phase IIa Pancreatic Cancer Study of Namodenoson at ESMO 2026
26-OCT-2026 07:00 AM ET
Share this post
More filings for $CANF
CANF ▲ +6.5% - Can-Fite BioPharma Ltd.Nov 12, 2026CANF ▲ +9.2% - Can-Fite BioPharma Ltd.Nov 9, 2026CANF ▲ +6.2% - Can-Fite BioPharma Ltd.Nov 2, 2026CANF ▲ +1.8% - Can-Fite BioPharma Ltd.Sep 9, 2026CANF ▲ +3.1% - Can-Fite BioPharma Ltd.Sep 8, 2026CANF ▼ -13.1% - Can-Fite BioPharma Ltd.Sep 2, 2026
View full $CANF filing history →💬 Comments
Loading comments…
Leave a comment